Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04382300 | Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions | unknown | Phase 2 | 39 | Shanghai Chest HospitalOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT03006575 | Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung Cancer | unknown | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04706949 |
| Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment |
| unknown |
| Phase 2 |
| 26 |
| Fudan UniversityOTHER |
| 1 |
| Jan 13, 2021 |
| clinicaltrials |
| NCT04636593 | A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC | unknown | Phase 2 | 43 | First People's Hospital of HangzhouOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT04390984 | Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients | unknown | Phase 1 | 22 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04675008 | Central Nervous System(CNS) Efficacy of Dacomitinib | unknown | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT04692935 | Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis | unknown | — | 450 | Jun WangOTHER | 0 | Jan 5, 2021 | clinicaltrials |
| NCT04448379 | Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 | 48 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 28, 2020 | clinicaltrials |
| NCT03803137 | Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection(Onco-VOC) | unknown | N/A | 50 | Hopital FochOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT04669730 | Baduanjin Exercise on Meridian Energy, Lung Function and Heart Rate Variability in Patients Undergoing Lung Operative. | unknown | N/A | 120 | Tzu Chi UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04672759 | A Real-world Study of Durvalumab for Lung Cancer in China | unknown | — | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04667975 | The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy(CKD-702) | unknown | Phase 1 | 74 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT03254004 | Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm | unknown | Phase 2 | 70 | Samsung Medical CenterOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04654520 | A Randomized Study of Primary Tumor Radiotherapy for Patients With Stage Ⅳ NSCLC | unknown | N/A | 290 | Guizhou Medical UniversityOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04393883 | A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC) | unknown | N/A | 216 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT04641754 | A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer | unknown | Phase 2 | 176 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2020 | clinicaltrials |
| NCT00410683 | Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery(LUNG ART) | unknown | Phase 3 | 500 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04619537 | A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT04619563 | A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT04631146 | Efficacy and Safety of Camrelizumab in Real-World Study | unknown | — | 450 | Guangdong Association of Clinical TrialsOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT02977169 | To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03402048 | The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial(EPIC) | unknown | Phase 3 | 567 | University of Turin, ItalyOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04612673 | A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC | unknown | Phase 2 | 33 | China Medical University, ChinaOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04613804 | Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04102982 | Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer(MWA in NSCLC) | unknown | Phase 2 | 200 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03288870 | Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)(DOMINUS) | unknown | Phase 2 / Phase 3 | 218 | BiocadINDUSTRY | 2 | Oct 29, 2020 | clinicaltrials |
| NCT04604470 | Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2(I-SABR2_PDA) | unknown | — | 126 | Maastricht UniversityOTHER | 0 | Oct 27, 2020 | clinicaltrials |
| NCT04575415 | Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study(BELLA) | unknown | — | 272 | Guangdong Association of Clinical TrialsOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT04592666 | Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer(APPEAL) | unknown | Phase 2 | 226 | Fudan UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03048500 | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | unknown | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04553887 | Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial(AUTUMN) | unknown | Phase 2 | 53 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03481101 | WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC(WHENII) | unknown | N/A | 60 | Rigshospitalet, DenmarkOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04560244 | A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment | unknown | Phase 2 | 15 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 23, 2020 | clinicaltrials |
| NCT04554875 | Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules | unknown | — | 1,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT04553601 | Molecular Imaging Visualization of Tumor Heterogeneity in Non-small Cell Lung Cancer | unknown | N/A | 150 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT03502850 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 507 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04398940 | A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 71 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04544644 | A Study of Combination Therapy in NSCLC | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 0 | Sep 10, 2020 | clinicaltrials |
| NCT04506242 | Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer | unknown | Phase 2 | 74 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 9, 2020 | clinicaltrials |
| NCT04416035 | A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC(NSCLC) | unknown | Phase 3 | 608 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04530097 | Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLC | unknown | N/A | 260 | Shanghai 10th People's HospitalOTHER | 1 | Aug 28, 2020 | clinicaltrials |
| NCT04530708 | Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC(MARS) | unknown | N/A | 162 | Swedish Lung Cancer Study GroupNETWORK | 1 | Aug 28, 2020 | clinicaltrials |
| NCT03598517 | High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer | unknown | N/A | 50 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT04524299 | Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLC | unknown | Phase 2 | 160 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT04136470 | BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics | unknown | — | 130 | ArdigenINDUSTRY | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04500704 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC(ACROSS1) | unknown | Phase 3 | 166 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04500717 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation(ACROSS2) | unknown | Phase 3 | 460 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT03267654 | Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance | unknown | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 3, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 28, 2021source: clinicaltrials